A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European ...

Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a ...

With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.

The differences in the dividends these three companies paid on the same day tell three very different income stories.

Merck has decided to discontinue production of a combination antibiotic used in hospitals to target life-threatening ...

Merck (NYSE:MRK) reported FDA approval of WELIREG plus LENVIMA for adults with advanced renal cell carcinoma after prior PD-1 ...

Oct 7 (Reuters) - Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor against Merck, ordering the drugmaker to halt the manufacture and sale of injectable ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s ...

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

Halozyme previously sued Merck in Germany, and the company said it was granted a preliminary injunction late last year to stop the launch of Keytruda SC in the country. Halozyme has also sued Merck ...

The medicines Merck sells today grew at their usual pace. What investors spent the year repricing was everything that comes next.